Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Strong evidence for ALS often comes from familial forms of the disease, where specific gene mutations— for example in the ...

Cure Rare Disease has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of an antisense oligonucleotide therapy for ...

In this study, we tested if locked nucleic acid (LNA) miR-181a-5p antisense oligonucleotides (ASO) could be used as a therapeutic to limit articular cartilage degeneration. Methods We used a variety ...

Less than a month after researchers unveiled that a “ticking DNA clock” is behind Huntington’s disease (HD), scientists have ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Neurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.

Warfarin was associated with more risk than apixaban (Eliquis; 55.38 vs 21.42 per 1,000 person-years, HR 2.60, 95% CI ...

One of Australia's biggest pathology providers reports that GP visits and pathology volumes remain well below the historical ...